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Introduction
Despite complete resection of their primary tumors, breast
cancer patients still harbor a considerable risk of metastatic
relapse caused by minimal residual disease (MRD). To
identify single disseminated tumor cells (DTC) in the bone
marrow (BM) and circulating tumor cells (CTC) in the peri-
pheral blood undetectable even by high-resolution imaging
technologies, sensitive and specific assays have been
developed [1,2].
BM plays the most prominent role among the distant organs
as an indicator organ for MRD. Moreover, BM appears to be
a common homing organ for DTC derived from various types
of epithelial tumors [3]. Although BM is easily accessible by
aspiration through the iliac crest and is a routine diagnostic
method for patients with leukemias and lymphomas, BM
analysis is an invasive procedure not yet introduced in the
clinical management of solid tumor patients. In contrast,
peripheral blood analyses are more convenient and less
stressful for patients than BM analyses, and many research
groups are currently evaluating the clinical utility of CTC for
assessment of prognosis and monitoring of systemic therapy.
Previous findings suggest that DTC/CTC are capable of
surviving chemotherapy probably by persisting in a dormant
nonproliferating state for many years [4,5]. Detection and
characterization of DTC/CTC provide the potential to monitor
systemic tumor cell dissemination in BM and blood, and to
identify therapeutic targets on DTC/CTC that might
contribute to an improved individualized targeted treatment of
cancer patients.
Detection of disseminated tumor
cells/circulating tumor cells
Several methods for the detection of DTC/CTC from BM
aspirates and blood have been developed to enrich these
rare cells [6,7]. Methods to screen BM aspirates or peripheral
blood for DTC/CTC after enrichment can be classified into
cytometric/immunological approaches and molecular
approaches [1,8,9]. Detection by immunocytochemistry [3,8]
enables the characterization of both cell size and shape as
well as the nucleus–cytoplasm relationship of each individual
event, thereby excluding BM-derived or blood cells with weak
expression of the protein of interest. Because of the absence
of tumor-specific target antigens, epithelial-specific antigens
such as cytoskeleton-associated cytokeratins, surface adhe-
sion molecules, or growth factor receptors are still the
markers of choice for the detection of DTC/CTC [1,8]. To
overcome the problem of strongly varying detection rates of
DTC/CTC in BM and blood from nonmetastatic breast
cancer patients (for review see [2,10]), a concept for the
detection and enrichment of DTC in BM has been proposed
that includes criteria to evaluate morphology and staining
results after automatic microscopic screening [11-14].
Viable DTC/CTC defined by their ability to secrete individual
proteins after short-term culture can be detected by the
EPISPOT (epithelial immunospot) technique. Using this
approach, Muc-1-secreting and/or CK19-secreting DTC could
be demonstrated in BM samples of breast cancer patients
with (90%) and without (50%) overt metastases [15].
Furthermore, in a small series of 45 breast cancer patients,
the detection of full-length CK19 released by cells using this
technique correlated with the presence of overt metastasis
and a reduced survival [16].
Progress towards a standardized method for CTC detection
in peripheral blood was reached through the introduction of
the CellSearch system (Veridex, Warren, NJ, USA), an
automated enrichment and immunostaining device that has
been cleared by the US Food and Drug Administration for the
detection of CTC in patients with metastatic breast cancer,
colon cancer and prostate cancer [17-24]. Furthermore, with
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the recently presented CTC-chip – a microfluid platform
consisting of anti-EpCAM antibody-coated microposts
capable of capturing CTC from unfractionated blood under
precisely controlled laminar flow conditions – Nagrath and
colleagues detected CTC in almost all cancer patients
independent of the stage of the disease [25]. CTC counts 2
to 3 log units higher than those obtained by the US Food and
Drug Administration-approved method were reported by
Pachmann and colleagues in nearly 100% of breast cancer
patients using the MAINTRAC™ assay. In this analysis, after
erythrocyte lysis, fluorescently labeled EpCAM-positive/
CD45-negative cells are counted by laser scanning cytometry
[26]. Furthermore, ultraspeed automated digital microscopy
fiberoptic array scanning technology and laser printing tech-
niques allow ultrafast evaluation of images [27-29]. Very
recently, Talasaz and colleagues presented a new sample
preparation technology, the MagSweeper – an automated
immunomagnetic separation technology [30].
RT-PCR to detect epithelium-specific or rather organ-specific
transcripts such as CK19 and CK20, HER2 or mammaglobin
has also been proven promising to detect DTC/CTC [31-38].
Very recently, the AdnaTest Breast Cancer Detect for
analyzing tumor-associated mRNA for HER2, MUC1 or GA
733-2 was described for the detection of CTC in blood from
primary breast cancer patients [39]. The main drawback of
RT-PCR approaches are false positive results due to a low
level of epithelial-related or tissue-related transcription in
normal cells [40-42]. Moreover, heterogeneity in the expres-
sion levels of a particular target transcript between individual
DTC/CTC cannot be predicted by RT-PCR. Nevertheless,
several studies provided evidence for a clinical relevance of
DTC/CTC detected by RT-PCR (for a review see [2,10]). The
advantages and disadvantages of the mentioned detection
approaches have been recently discussed elsewhere [7].
Characterization of disseminated tumor
cells/circulating tumor cells
DTC are likely to be genomically unstable and heterogeneous
[43] as well as capable of disseminating in a less progressed
genomic state, acquiring genomic alterations typical for fully
metastatic cells later [44]. Furthermore, DTC are hetero-
geneous regarding the expression of growth factor receptors,
adhesion molecules, proteases and their inducer and recep-
tors, major histocompatibility complex antigens, signaling
kinases, melanoma-associated antigens or telomerase activity
[1,3,45-51].
Of particular importance is the epidermal growth factor
receptor HER2, the expression of which in primary tumors is
the basis for trastuzumab treatment decisions of breast
cancer patients [52,53]. HER2 overexpression on DTC in BM
was predictive for a poor clinical outcome of stage I to stage
III breast cancer patients [54]. The study of Vincent-Salomon
and colleagues demonstrated that in the majority of cases the
HER2 status remained stable between DTC and the corres-
ponding primary tumors [55]. There is also evidence,
however, for discrepancies between the HER2 status of
primary tumors and that of DTC in BM [54,56], or CTC in
blood [57-59]. This discrepancy might be due to the
presence of a small subclone of HER2-amplified cells missed
by routine fluorescence in situ hybridization analysis of the
primary tumor or an acquisition of HER2 gene amplification in
DTC/CTC after dissemination [57].
For CTC from patients with metastatic breast cancer, global
gene expression profiles have been defined and a list of CTC-
specific genes obtained, which might be useful to distinguish
a normal control phenotype from cancer patients [60].
TWIST1, a transcription factor pivotal for metastasis by
promoting epithelial–mesenchymal transition [61-64], was
part of the gene expression signature identified in EpCAM-
enriched cells from BM of breast cancer patients after
chemotherapy. Its expression was associated with distant
metastasis and local progression [65]. The first hints for stem
cell features of DTC in BM were provided by Balic and
colleagues and by Alix-Panabieres and colleagues, who
demonstrated a significant number of DTC from BM of breast
cancer patients with either CD44+/CD24–/low or CK19+/Muc-1–
stem cell-like phenotypes [15,66]. With the AdnaTest Tumor
Stem Cell/The AdnaTest EMT RT-PCT assay, Aktas and
colleagues found that a major proportion of CTC from
metastatic breast cancer patients showed features charac-
teristic for stem cells and epithelial–mesenchymal transition
[67]. Resistance to systemic chemotherapy and long-term
persistence of DTC in BM of cancer patients is also indicative
for a putative stem cell phenotype [68-70].
To perform functional studies for the validation of the descrip-
tive findings observed in cancer patients, the development of
appropriate mouse models mimicking MRD is pivotal.
Clinical relevance of disseminated tumor
cells/circulating tumor cells
The meta-analysis published by Braun and colleagues, includ-
ing data for 4,703 breast cancer patients, demonstrated that
the presence of DTC in BM was not only predictive of the
development of skeletal metastases but also predicted the
development of metastases in other organs [71].
Based on these data and other results showing clinical rele-
vance of DTC/CTC detection in breast cancer patients
[7,10], DTC and CTC were mentioned for the first time in the
American Society of Oncology recommendations on tumor
markers in 2007 [72].
The ability of DTC to survive chemotherapy and hormonal
therapy [5,68] and the persistence in BM over many years
post surgery, linked to an increased risk of late metastatic
relapse, have been described previously [69,70,73,74]. A
European pooled analysis involving 696 breast cancer
patients revealed that the persistence of DTC in 16% ofbreast cancer patients was an independent prognostic factor
for subsequent reduced breast cancer survival [75,76].
Bidard and colleagues recently reported about the prognos-
tic relevance of DTC detection in stage I to stage III breast
cancer patients [77]. As also published by Bidard and
colleagues, the presence of DTC in BM was associated with
a different pattern of loco-regional cancer cell dissemination
and might influence loco-regional recurrence-free survival.
Hormonal therapy and radiotherapy could help to prevent
reseeding of the primary tumor area by DTC [78].
Sequential peripheral blood analyses are more convenient
than BM analyses. Only few studies have thus far directly
compared BM and blood analyses in the same patients
[5,79-82], and only studies on larger cohorts of patients may
help to clarify whether BM analysis can be replaced by a
blood test.
CTC analyses for therapy monitoring have provided signifi-
cant prognostic information in metastatic breast cancer.
Cristofanilli and colleagues showed that the number of CTC
before treatment and at the first follow-up visit after initiation
of therapy is an independent predictor of progression-free
survival and overall survival [17]. Moreover, results by Hayes
and colleagues indicated that CTC in peripheral blood of
metastatic cancer patients at any time during therapy directly
reflect the patient’s response, or lack of response, respec-
tively, to therapy [20] – and CTC seem to be superior or
additive to conventional imaging methods such as radiologic
assessment, including computed tomograms [83,84]. Despite
these promising data, however, the recent American Society
of Oncology guidelines have stated that even the use of the
US Food and Drug Administration-cleared CellSearch assay
in patients with metastatic breast cancer cannot be
recommended until further validation confirms the clinical
value of this test [72]. The clinical utility of CTC measure-
ments in metastatic breast cancer patients is therefore now
being prospectively addressed in the randomized trial
SWOG S0500 led by the Southwest Oncology group [85],
expecting to enroll 500 patients with metastatic breast
cancer.
To monitor MRD in nonmetastatic patients is the most impor-
tant challenge of new DTC/CTC technologies. In a phase II
trial (REMAGUS 02), Pierga and colleagues monitored CTC
in 118 patients with large operable or locally advanced breast
cancer before and after neoadjuvant chemotherapy, and
showed that the presence of CTC after a short follow-up time
of 18 months was an independent prognostic factor for
reduced metastasis-free survival [86]. Interestingly, they did
not find a significant correlation for response of the primary
tumor to chemotherapy. In contrast, follow-up analyses of
two German trials using the CellSearch technology – the
GEPARQuattro trial on neoadjuvant chemotherapy and
additionally, if indicated, trastuzumab treatment, and the
SUCCESS trial on adjuvant chemotherapy – are still
ongoing and will show whether the observed decreases in
CTC rates will be associated with an improved survival rate
[87,88]. Very recently, Xenidis and colleagues described
patients with detectable CK19 mRNA post chemotherapy
having significantly reduced overall survival and disease-free
survival [38].
Conclusions
Detection of DTC in BM and of CTC in blood of breast
cancer patients years before the occurrence of distant overt
metastases is facilitated by several rare cell detection
techniques. The resulting information may be used to assess
the individual prognosis of cancer patients and to stratify the
patients at risk to systemic therapies aimed to prevent
recurrences and metastatic relapses. Nevertheless, the
detection of DTC/CTC is still not part of the routine tumor
staging in clinical practice. DTC/CTC measurements within
clinical trials, however, might provide an important biomarker
for real-time monitoring of the efficacy of systemic therapies
in individual cancer patients, which may accelerate drug
development, help to define subpopulations of patients with
the highest treatment benefit, and open a new avenue for
investigating drug resistance.
Recent data support the hypothesis that DTC are able to
persist in the BM in a dormant state and that the BM provides
a reservoir out of which DTC might disseminate also in other
organs, such as the lung, the liver and the brain [89]. To
understand molecular mechanisms involved in the regulation
of the dormant stage together with the identification of those
DTC/CTC that have the potential to initiate metastases are
the most challenging topics of basic research on the biology
of these cells.
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